Treatment of mastocytosis: pharmacologic basis and current concepts.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0145-2126(01)00039-XPMID 11377684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic criteria and classification of mastocytosis: a consensus proposal.

  2001cited by this paper
• Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.

  2000cited by this paper
• The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils

  2000cited by this paper
• HIV-1 gp120 Induces IL-4 and IL-13 Release from Human FcεRI+ Cells Through Interaction with the VH3 Region of IgE1

  2000cited by this paper
• Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis

  2000cited by this paper
• Rhinology Abstracts

  2000cited by this paper
• Bacterial Immunoglobulin Superantigen Proteins A and L Activate Human Heart Mast Cells by Interacting with Immunoglobulin E

  2000cited by this paper
• Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα

  2000cited by this paper
• Tat Protein Is an HIV-1-Encoded β-Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human FcεRI+ Cells1

  2000cited by this paper
• Mast cells and basophils

  2000cited by this paper
• Chapter 33 – Lipid Mediators from Mast Cells and Basophils in Allergic Diseases

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.

  2000cited by this paper
• Stem cell factor is localized in, released from, and cleaved by human mast cells.

  1999cited by this paper
• Human Basophils and Mast Cells.

  1999cited by this paper
• Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

  1999cited by this paper
• Correction: Treatment of Asthma with Drugs Modifying the Leukotriene Pathway.

  1999cited by this paper
• Treatment of asthma with drugs modifying the leukotriene pathway.

  1999cited by this paper
• Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis

  1998cited by this paper
• Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

  1998cited by this paper
• Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c‐kit mutation Asp‐816 to Val

  1998cited by this paper
• Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE.

  1998cited by this paper
• Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man

  1997cited by this paper
• Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis.

  1997cited by this paper
• Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems.

  1997cited by this paper
• Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α

  1996cited by this paper
• Eosinophil granule proteins activate human heart mast cells.

  1996cited by this paper
• Treatment of three patients with systemic mastocytosis with interferon alpha-2b.

  1996cited by this paper
• A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone.

  1996cited by this paper
• Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

  1996cited by this paper
• Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization.

  1996cited by this paper
• Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization.

  1995cited by this paper
• Heterogeneity of human mast cells based on cytokine content.

  1995cited by this paper
• Human Basophils and Mast Cells: Clinical Aspects

  1995cited by this paper
• Biology, diagnosis and therapy of mastocytosis.

  1995cited by this paper
• Radiotherapy of Refractory Bone Pain Due to Systemic Mast Cell Disease

  1994cited by this paper
• Heterogeneity of Mediator Release From Human Basophils and Mast-cells Induced By Contrast-media (cm)

  1994cited by this paper
• Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.

  1993cited by this paper
• Leukotriene E4 and granulocytic infiltration into asthmatic airways.

  1993cited by this paper
• Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.

  1993cited by this paper
• Basophil and mast cell lineages in vitro and in vivo.

  1992cited by this paper
• Basophil and Mast Cell Lineages In Vitro and In Vivo

  1992cited by this paper
• Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release.

  1992cited by this paper
• Anti-inflammatory effect of cyclosporin A on human skin mast cells.

  1992cited by this paper
• Response to interferon alfa-2b in a patient with systemic mastocytosis.

  1992cited by this paper
• Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition.

  1991cited by this paper
• Heterogeneity of human mast cells and basophils in response to muscle relaxants.

  1991cited by this paper
• Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

  1991cited by this paper
• The treatment of mastocytosis: an overview.

  1991cited by this paper
• Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.

  1991cited by this paper
• Characterization of the anti-inflammatory effect of FK-506 on human mast cells.

  1991cited by this paper
• The treatment of mastocytosis: an overview.

  1991cited by this paper
• FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells.

  1991cited by this paper
• Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. Southampton, Bermuda, June 15, 1990.

  1991cited by this paper
• Splenectomy in the management of systemic mast cell disease.

  1990cited by this paper
• Specific high‐affinity receptors for interferon‐γ on mouse bone marrow‐derived mast cells: inhibitory effect of interferon‐γ on mast cell precursors

  1990cited by this paper
• Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells.

  1990cited by this paper
• Isotope-edited NMR of cyclosporin A bound to cyclophilin: evidence for a trans 9,10 amide bond.

  1990cited by this paper
• Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.

  1990cited by this paper
• Molecular cloning and overexpression of the human FK506-binding protein FKBP

  1990cited by this paper
• Anaesthetic management of systemic mastocytosis.

  1990cited by this paper
• Specific high-affinity receptors for interferon-gamma on mouse bone marrow-derived mast cells: inhibitory effect of interferon-gamma on mast cell precursors.

  1990cited by this paper
• Cromolyn sodium in the management of systemic mastocytosis.

  1990cited by this paper
• A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis.

  1989cited by this paper
• Human basophil/mast cell releasability. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics.

  1989cited by this paper
• Human basophil/mast cell releasability. VII. Heterogeneity of the effect of adenosine on mediator secretion.

  1989cited by this paper
• Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen‐induced weal‐and‐flare response and a reduction in skin mast cell numbers and histamine content

  1989cited by this paper
• Protein kinase C (PKC) changes in human basophils. IgE-mediated activation is accompanied by an increase in total PKC activity.

  1989cited by this paper
• Adenosine potentiates mediator release from human lung mast cells.

  1988cited by this paper
• Effects of a specific inhibitor of the 5-lipoxygenase pathway on mediator release from human basophils and mast cells.

  1988cited by this paper
• Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin.

  1987cited by this paper
• Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption.

  1987cited by this paper
• Mastocytosis with malabsorption, myelofibrosis, and massive ascites.

  1987cited by this paper
• Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells.

  1987cited by this paper
• Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge.

  1987cited by this paper
• Intractable ascites in systemic mastocytosis treated by portal diversion

  1987cited by this paper
• Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias.

  1986cited by this paper
• Calmodulin, cyclophilin, and cyclosporin A.

  1986cited by this paper
• [The role of protein kinase C in cell surface signal transduction and tumor promotion].

  1986cited by this paper
• Effect of activation of the H1 receptor on coronary hemodynamics in man.

  1986cited by this paper
• Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial.

  1985cited by this paper
• Complement- and IgE-mediated release of histamine from basophils in vitro. V. Differential effects of drugs modulating arachidonic acid metabolism.

  1985cited by this paper
• The pharmacologic modulation of the release of arachidonic acid metabolites from purified human lung mast cells.

  1985cited by this paper
• Treatment of urticaria pigmentosa with corticosteroids.

  1985cited by this paper
• Evidence for an adenosine A2/Ra receptor on human basophils.

  1985cited by this paper
• Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol.

  1984cited by this paper
• Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations.

  1984cited by this paper
• The role of protein kinase C in cell surface signal transduction and tumour promotion

  1984cited by this paper
• Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa.

  1983cited by this paper
• Intervention with epinephrine in hypotension associated with mastocytosis.

  1983cited by this paper
• Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells.

  1983cited by this paper
• Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells.

  1982cited by this paper
• Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope.

  1982cited by this paper
• Inhibition of basophil histamine release by anti-inflammatory steroids

  1981cited by this paper
• Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate

  1981cited by this paper
• Possible role of phospholipase A2 in triggering histamine secretion from human basophils in vitro.

  1981cited by this paper
• Lipoxygenase products modulate histamine release in human basophils

  1981cited by this paper
• Physiologic manifestations of human anaphylaxis.

  1980cited by this paper
• An inhibitor of lipoxygenase inhibits histamine release from human basophils.

  1980cited by this paper
• Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro.

  1979cited by this paper

• Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review

  2022cites this paper
• Unconventional uses of common conventional drugs: A review.

  2021cites this paper
• A role for mast cells in geographic atrophy

  2020cites this paper
• CPAA_A_206615 77..92

  2019influential citation
• Novel approaches to treating advanced systemic mastocytosis

  2019influential citation
• Relevant updates in systemic mastocytosis.

  2019cites this paper
• Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology.

  2019cites this paper
• Urticaria pigmentosa presenting as cardiac emergency

  2017cites this paper
• [Urticaria pigmentosa: clinical and therapeutic aspects for the paediatrician].

  2017cites this paper
• Management of poorly controlled indolent systemic mastocytosis using narrowband UVB phototherapy.

  2017cites this paper
• [Urticaria pigmentosa: clinical and therapeutic aspects for the paediatrician].

  2016cites this paper
• Narrow‐band UVB phototherapy and psoralen–ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients

  2016cites this paper
• Diffuse Cutaneous Mastocytosis with Bullous Lesions and Pulmonary Involvement: A Rare Case

  2015cites this paper
• Current Concepts on Diagnosis and Treatment of Mastocytosis

  2014cites this paper
• Mastocytosis: update on pharmacotherapy and future directions

  2013cites this paper
• New insights into the pathogenesis, diagnosis, and management of mastocytosis.

  2012cites this paper
• Indolent systemic mastocytosis treated with narrow‐band UVB phototherapy: study of five cases

  2012cites this paper
• Identification of novel therapeutic targets in mastocytosis:Inhibition of survival of neoplastic mast cells by targeting IAPs and TRAIL receptors

  2011cites this paper
• Guidelines for the Diagnosis and Treatment of Cutaneous Mastocytosis in Children

  2011cites this paper
• Technical Advance: Soluble OX40 molecule mimics regulatory T cell modulatory activity on FcɛRI‐dependent mast cell degranulation

  2011cites this paper
• Mastocitosis cutánea: Revisión de 10 años de experiencia en el Servicio de Dermatología del Hospital General de Niños Pedro de Elizalde.

  2011cites this paper
• Wirksamkeit und Verträglichkeit des Raft-Interventionstherapeutikums Miltefosin bei der Behandlung der kutanen Mastozytose

  2010cites this paper
• La mastocitosi sistemica indolente e il trattamento con la fototerapia con UVB a banda stretta: studio di 4 casi

  2010cites this paper
• Prostaglandins and Other Lipid Mediators urvey of aspirin administration in systemic mastocytosis

  2009cites this paper
• Survey of aspirin administration in systemic mastocytosis.

  2009cites this paper
• Cutaneous vascular disorders associated with internal malignancy.

  2008cites this paper
• Mastocytosis in Children: A Protocol for Management

  2008cites this paper
• Antileukotriene drugs: clinical application, effectiveness and safety.

  2007cites this paper
• Progesterone increases csk homologous kinase in HMC‐1560 human mast cells and reduces cell proliferation

  2007cites this paper
• (—)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes

  2007cites this paper
• Unusual cutaneous findings of urticaria pigmentosa and telangiectasia macularis eruptiva perstans associated with marked myelofibrosis

  2006cites this paper
• Telangiectasia macularis eruptiva perstans: unusual presentation and treatment.

  2006cites this paper
• Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

  2006cites this paper
• Imatinib mesylate in the treatment of systemic mastocytosis

  2006cites this paper
• Treatment of systemic mastocytosis.

  2006cites this paper
• Mastozytosen ± Diagnostik, Klassifikation, Therapie, aktuelle pathophysiologische Ansätze

  2005cites this paper
• Erkrankungen des granulozytären/monozytären Systems

  2005cites this paper
• Unusual cutaneous findings of urticaria pigmentosa and telangiectasia macularis eruptiva perstans associated with marked myelofibrosis.

  2004cites this paper
• Brief Review: Advances in Therapy with Antileukotriene Drugs

  2004cites this paper
• Mastocytosis, Gastrointestinal Manifestations of

  2004cites this paper
• Mastocytosis: classification, diagnosis, and clinical presentation.

  2004cites this paper
• C-kit and Mastocytosis

  2004cites this paper
• Aggressive systemic mastocytosis mimicking sclerosing cholangitis.

  2004cites this paper
• ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

  2004cites this paper
• Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.

  2004cites this paper
• „Smouldering systemic mastocytosis“

  2004influential citation
• Advances in therapy with antileukotriene drugs.

  2004cites this paper
• A case of systemic mastocytosis associated with severe osteoporosis and pathologic fractures.

  2004cites this paper
• Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.

  2004cites this paper
• Management of mastocytosis.

  2003cites this paper
• Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study.

  2003cites this paper
• Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

  2003cites this paper
• Systemic mastocytosis

  2003cites this paper
• Diagnosis and treatment of systemic mastocytosis: state of the art

  2003influential citation
• Erkrankungen des Blutes

  2003cites this paper
• Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

  2002cites this paper
• [Mast cell leukemia].

  2002cites this paper
• Mastocytosis: current concepts in diagnosis and treatment

  2002cites this paper
• Diagnostic criteria and classification of mastocytosis: a consensus proposal.

  2001cites this paper